Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MPO | P05164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790413 | 0.91 | CHRM2 (0.53) | CHRM2L3MBTL1LMNAMPOKDM4E | |
| SCHEMBL4412179 | 0.90 | CHRM2 (0.56) | CHRM2L3MBTL1LMNAMPOKDM4E | |
| SCHEMBL4408020 | 0.89 | CHRM2 (0.55) | CHRM2L3MBTL1LMNAMPOKDM4E | |
| SCHEMBL16268751 | 0.84 | CHRM2 (0.58) | CHRM2L3MBTL1LMNAMPOKDM4E | |
| SCHEMBL184001 | 0.79 | LMNA (0.77) | CHRM2L3MBTL1LMNAMPOKDM4E | |
| SCHEMBL1796909 | 0.79 | LMNA (0.77) | CHRM2L3MBTL1LMNAMPOKDM4E | |
| SCHEMBL4409223 | 0.79 | HTT (0.41) | CHRM2L3MBTL1ALDH1A1HDAC3HDAC1 | |
| SCHEMBL10045186 | 0.78 | CHRM2 (0.88) | CHRM2L3MBTL1LMNAMPOKDM4E | |
| SCHEMBL4502698 | 0.78 | MEN1 (0.70) | CHRM2MPOMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6077029 | 0.77 | LMNA (0.74) | CHRM2L3MBTL1LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608352-B1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2009-12-30 | — | — | EP | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| EP-1608352-A4 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2007-11-28 | — | — | EP | disclosed |
| EP-1608352-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | Taigen Biotechnology (TW) | 2005-12-28 | — | — | EP | disclosed |
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2005-02-24 | — | — | US | disclosed |
| WO-2004089360-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY (TW) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | CCL2, CCR2, CCR5 | CHRM2 1362/4885L3MBTL1 2576/4885LMNA 4316/4885 |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | SRM, SMS, SMOX | CHRM2 2755/4885L3MBTL1 1477/4885LMNA 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.